There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cara Therapeutics (CARA – Research Report) and Penumbra (PEN – Research Report) with bullish sentiments. Cara Therapeutics (CARA) Needham analyst Joseph Stringer reiterated a Buy rating on Cara Therapeutics today and set a price target of $26.00. The company's shares closed last Thursday at $9.37. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cara-therapeutics-cara-and-penumbra-pen?utm_source=advfn.com&utm_medium=referral
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Cara Therapeutics Charts.
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Cara Therapeutics Charts.